The firm will use the grant to expedite the development of tests to identify more than 25 bacterial pathogens and antibiotic resistance markers in whole blood samples.
According to project organizers, feasibility testing in the first phase of the project was successful and clinical trials are planned for later this year.
The device being developed will interpret the scattered patterns of light that has passed through the body to enable cellular-level imaging and will compete with biopsies and blood tests.
The test would also be used to detect antibiotic susceptibility. Fraunhofer received £900,000 from SBRI Healthcare in support of the project to develop the test.
The Codex4SMEs project, which has a €3.1 million budget, involves seven countries to increase cooperation in Europe's northwest region to develop companion diagnostics.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
The Swedish firm will use its CETSA technology to profile the effects of a drug on up to 6,000 proteins from patient blood samples.
The SEK4.9 million ($585,000) grant will support development studies for the firm's Immray PanCan-d blood based test for the early detection of pancreatic cancer.